Global Wet Macular Degeneration Market Size By Type (Lucentis, Eylea), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Wet Macular Degeneration Market was valued at USD 9.8 billion in 2023 and is projected to reach USD 17.6 billion by 2031, expanding at a CAGR of 7.6% during the forecast period from 2023 to 2031. The market is primarily driven by the rising prevalence of age-related macular degeneration (AMD), increasing geriatric population, and the growing adoption of anti-VEGF therapies. Technological advancements in diagnostic imaging and treatment methods are further enhancing early detection and efficient management of the disease, contributing significantly to market expansion.

Drivers:

1. Increasing Prevalence of AMD:

The global incidence of age-related macular degeneration, especially the wet form, is rising due to the aging global population. Wet AMD is a leading cause of vision loss among individuals over 60, necessitating ongoing medical interventions and treatments.

2. Advancements in Therapeutics:

Innovative therapies, particularly anti-VEGF (vascular endothelial growth factor) treatments such as ranibizumab, aflibercept, and faricimab, have revolutionized disease management by significantly improving patient outcomes and slowing progression.

3. Rising Geriatric Population:

A growing elderly population worldwide significantly boosts the demand for wet AMD treatments, as the risk of developing the condition increases with age.

Restraints:

1. High Cost of Treatment:

Wet AMD treatments are expensive, with frequent intraocular injections required. This makes long-term therapy burdensome, especially in low- and middle-income countries, limiting access and adoption.

2. Limited Awareness and Early Diagnosis:

In some regions, lack of awareness and delayed diagnosis hinder timely treatment, leading to irreversible vision loss. Early detection remains a key challenge.

Opportunity:

1. Emerging Markets Expansion:

Developing countries in Asia-Pacific and Latin America present untapped potential, driven by healthcare infrastructure improvements, increasing awareness campaigns, and growing access to diagnostics.

2. Development of Long-Acting Therapies:

Research into gene therapies and long-acting drug delivery systems aims to reduce treatment frequency, enhance patient compliance, and improve outcomes, offering promising opportunities for growth.

Market by System Type Insights:

Based on treatment type, the anti-VEGF injection segment accounted for the largest share of the global market in 2023. These injections remain the cornerstone of wet AMD treatment, owing to their proven efficacy. However, emerging therapies, including gene therapy and sustained-release implants, are expected to witness the fastest growth due to enhanced convenience and reduced treatment burden.

Market by End-use Insights:

In 2023, hospital-based eye clinics dominated the market owing to the availability of specialized ophthalmologists, advanced diagnostic equipment, and streamlined care pathways. Ambulatory surgical centers are expected to grow rapidly during the forecast period due to reduced procedure costs and shorter waiting times.

Market by Regional Insights:

North America held the largest share of the wet macular degeneration market in 2023, supported by a high prevalence of AMD, strong reimbursement frameworks, and the presence of leading pharmaceutical companies. Asia-Pacific is forecasted to witness the highest CAGR during the forecast period, driven by aging populations in countries such as Japan and China and improvements in healthcare accessibility.

Competitive Scenario:

Key players in the Global Wet Macular Degeneration Market include Roche Holding AG (Genentech), Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Alcon Inc., Bausch + Lomb, and Kubota Vision Inc. These companies focus on strategic collaborations, R&D investments, and new therapy launches.

In 2023, Roche launched Vabysmo (faricimab) in multiple markets, offering a dual pathway inhibition mechanism for longer-lasting control.

In 2024, Kubota Vision progressed clinical trials for its home-based monitoring wearable device aimed at early detection of wet AMD progression.

Scope of Work – Global Wet Macular Degeneration Market

Key Market Developments:

July 2023: Genentech’s Vabysmo received expanded regulatory approval for extended dosing intervals in the U.S. and Europe.

March 2024: Regeneron initiated trials for a port delivery system for aflibercept aimed at reducing injection frequency.

February 2024: Bausch + Lomb partnered with a leading AI diagnostics company to integrate retinal imaging for AMD screening in teleophthalmology networks.

FAQs:

1) What is the current market size of the Global Wet Macular Degeneration Market?

The market was valued at USD 9.8 billion in 2023.

2) What is the major growth driver of the Global Wet Macular Degeneration Market?

The primary growth driver is the increasing prevalence of age-related macular degeneration and the rising adoption of anti-VEGF therapies.

3) Which is the largest region during the forecast period in the Global Wet Macular Degeneration Market?

North America is the largest regional market, driven by a high disease burden and advanced healthcare infrastructure.

4) Which segment accounted for the largest market share in the Global Wet Macular Degeneration Market?

The anti-VEGF injection segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Wet Macular Degeneration Market?

Key players include Roche Holding AG, Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Alcon Inc., and Bausch + Lomb.